US 7208161 B1 - Production Of Attenuated Parainfluenza Virus Vaccines From Cloned Nucleotide Sequences - The Lens - Free & Open Patent and Scholarly Search

Patents

US 7208161 B1

Production Of Attenuated Parainfluenza Virus Vaccines From Cloned Nucleotide Sequences

Published: Apr 24, 2007
Earliest Priority: May 23 1997
Family: 1
Cited Works: 96
Cited by: 12
Cites: 10
Sequences: 74
Additional Info: Cited Works Full text Published Sequence

Abstract

Isolated polynucleotide molecules provide recombinant PIV genomes and antigenomes for production of recombinant PIV vaccines. The recombinant genome or antigenome can be expressed with a nucleoprotein (N), phosphoprotein (P), and a large (L) polymerase protein to produce isolated infectious PIV particles. The recombinant PIV genome and antigenome can be modified to produce desired changes, for example to incorporate attenuating mutations from biologically derived PIV mutants or to create chimeric PIV clones, to generate attenuated, immunogenic viruses for vaccine use.

Claims

An isolated polynucleotide molecule comprising an operably linked i) transcriptional promoter operative in a mammalian cell or operative in vitro, ii) a polynucleotide sequence encoding a partial or complete human PIV genome, said polynucleotide comprising at least one sequence selected from the group consisting of the complement of nucleotide sequences of SEQ ID NOS: 61, 63, 65, 67, 69, 71 and 73, or
a polynucleotide encoding a partial or complete human PIV antigenome said polynucleotide comprising at least one nucleotide sequence selected from the group consisting of SEQ ID NOS: 61, 63, 65, 67, 69, 71 and 73, and

iii) a transcriptional terminator operative in a mammalian cell or operative in vitro.
The isolated polynucleotide molecule of claim 1, in which the polynucleotide ii) encodes a human PIV3 genome or antigenome.
An isolated polynucleotide molecule comprising an operably linked i) transcriptional promoter operative in a mammalian cell or operative in vitro, ii) a polynucleotide sequence encoding a partial or complete human PIV genome said polynucleotide comprising the complement of nucleotide sequences of SEQ ID NOS: 69, 71 and 73, or
a polynucleotide encoding a partial or complete human PIV antigenome said polynucleotide comprising the nucleotide sequences of SEQ ID NOS: 69, 71 and 73, and

iii) a transcriptional terminator operative in a mammalian cell or operative in vitro.
The isolated polynucleotide of claim 3, in which the polynucleotide ii) is a polynucleotide sequence encoding a partial or complete human PIV3 genome and comprising the complement of nucleotide sequences of SEQ ID NOS: 69, 71 and 73, or
is a polynucleotide encoding a partial or complete human PIV3 antigenome and comprising the nucleotide sequences of SEQ ID NOS: 69, 71 and 73.
An isolated polynucleotide molecule comprising an operably linked transcriptional promoter operative in a mammalian cell or operative in vitro, a polynucleotide sequence encoding a chimeric partial or complete PIV genome or antigenome comprising said chimeric partial or complete partial or complete PIV genome or antigenome, and a transcriptional terminator operative in a mammalian cell or operative in vitro,
wherein said polynucleotide sequence encoding said chimeric partial or complete PIV genome or antigenome comprises a polynucleotide sequence of a background partial or complete PIV genome or antigenome and at least one heterologous PIV sequence selected from a HPIV 1 sequence, a HPIV 2 sequence, a HPIV 3 sequence, a BPIV sequence or a MPIV sequence,

and wherein said polynucleotide sequence encoding said chimeric partial or complete PIV genome or antigenome comprises a polynucleotide encoding the L protein of the wild-type of said background PIV or of said heterologous PIV.
The isolated polynucleotide of claim 5, in which the polynucleotide sequence encoding the background partial or complete PIV genome or antigenome further includes at least one mutation at a position corresponding to a position in the genome of HPIV3 selected from the group consisting of Val96 of the N protein, Ser389 of the N protein, Ile96 of the C protein, Pro199 of the M protein, Ile420 of the F protein, Ala450 of the F protein, Val384 of the HN protein, nucleotide 23 of the 3′ leader sequence, nucleotide 24 of the 3′ leader sequence, nucleotide 28 of the 3′ leader sequence, nucleotide 45 of the 3′ leader sequence and nucleotide 62 in the N gene start sequence.
The isolated polynucleotide of claim 5, in which the chimeric partial or complete PIV genome or antigenome comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein or of a F glycoprotein.
The isolated polynucleotide of claim 6, in which the chimeric partial or complete PIV genome or antigenome comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein or of a F glycoprotein.
The isolated polynucleotide of claim 6, in which the heterologous PIV sequence is from HPIV1.
The isolated polynucleotide of claim 7, in which the heterologous PIV sequence is from HPIV1.
The isolated polynucleotide of claim 5, that comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein and a heterologous PIV sequence that encodes an open reading frame of a F glycoprotein.
The isolated polynucleotide of claim 6, that comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein and a heterologous PIV sequence that encodes an open reading frame of a F glycoprotein.
The isolated polynucleotide of claim 11, in which both of the heterologous PIV sequences are from HPIV1.
The isolated polynucleotide of claim 12, in which both of the heterologous PIV sequences are from HPIV1.
The isolated polynucleotide of claim 11, in which the heterologous PIV sequence is a gene segment encoding a portion of an open reading frame of a HN or F glycoprotein comprising an antigenic domain or epitope or the cytoplasmic tail portion of said HN or F glycoprotein and replaces the counterpart gene segment of said background PIV sequence to form an open reading frame encoding a chimeric glycoprotein.
An isolated polynucleotide molecule comprising an operably linked transcriptional promoter operative in a mammalian cell or operative in vitro, a polynucleotide sequence encoding a chimeric partial or complete PIV genome or antigenome that includes at least one point mutation comprising said partial or complete PIV genome or antigenome, and a transcriptional terminator operative in a mammalian cell or operative in vitro,
wherein said polynucleotide sequence encoding said partial or complete PIV genome or antigenome comprises a polynucleotide sequence of a background partial or complete PIV genome or antigenome and at least one heterologous PIV sequence selected from a HPIV 1 sequence, a HPIV 2 sequence, a HPIV 3 sequence a BPIV sequence or a MPIV sequence,

and wherein said polynucleotide sequence encoding said partial or complete PIV genome or antigenome comprises a polynucleotide encoding the L protein of the wild-type of said background PIV or of said heterologous PIV.
The isolated polynucleotide of claim 16, in which the chimeric partial or complete PIV genome or antigenome comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein or of a F glycoprotein.
The isolated polynucleotide of claim 16, in which the heterologous PIV sequence is from HPIV1.
The isolated polynucleotide of claim 17, in which the heterologous PIV sequence is from HPIV1.
The isolated polynucleotide of claim 16, that comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein and a heterologous PIV sequence that encodes a F glycoprotein.
The isolated polynucleotide of claim 20, in which both of the heterologous PIV sequences are from HPIV1.
An isolated polynucleotide molecule comprising an operably linked transcriptional promoter operative in a mammalian cell or operative in vitro, a polynucleotide sequence encoding a chimeric partial or complete PIV genome or antigenome, and a transcriptional terminator operative in a mammalian cell or operative in vitro, wherein said polynucleotide sequence encoding said chimeric partial or complete PIV genome or antigenome comprises a polynucleotide sequence encoding a background partial or complete PIV genome or antigenome and at least one heterologous PIV polynucleotide sequence selected from a HPIV 1 sequence, a HPIV 2 sequence, a HPIV 3 sequence, a BPIV sequence or a MPIV sequence,
wherein said heterologous PIV polynucleotide sequence comprises a transcription unit comprising a polynucleotide sequence encoding an open reading frame of a protein of said heterologous PIV or portion thereof providing an antigenic determinant that is inserted between a gene start sequence and a gene end sequence of the PIV of the background.
The isolated polynucleotide of claim 22, in which the heterologous PIV polynucleotide sequence replaces an open reading frame of a gene of the background PIV.
The isolated polynucleotide of claim 22, in which the heterologous PIV nucleotide sequence is added to the genome or antigenome of the background PIV.
The isolated polynucleotide of claim 22, in which the polynucleotide sequence encoding the background partial or complete PIV genome or antigenome further includes at least one mutation at a position corresponding to a position in the genome of HPIV3 selected from the group consisting of Val96 of the N protein, Ser389 of the N protein, Ile96 of the C protein, Pro199 of the M protein, Ile420 of the F protein, Ala450 of the F protein, Val384 of the HN protein, Tyr942 of the L protein, Leu992 of the L protein, Thr1558 of the L protein, nucleotide 23 of the 3′ leader sequence, nucleotide 24 of the 3′ leader sequence, nucleotide 28 of the 3′ leader sequence, nucleotide 45 of the 3′ leader sequence and nucleotide 62 in the N gene start sequence.
The isolated polynucleotide of claim 22, in which the polynucleotide sequence encoding the background partial or complete PIV genome or antigenome further includes mutations at positions corresponding to a position in the genome of HPIV3 of Tyr942 of the L protein, Leu992 of the L protein and Thr1558 of the L protein.
The isolated polynucleotide of claim 22, in which the polynucleotide sequence that encodes the background partial or complete PIV genome comprises at least one nucleotide sequence that is the complement of a sequence selected from the group consisting of SEQ ID NOS: 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71 and 73,
or in which the polynucleotide sequence that encodes the background PIV antigenome comprises at least one nucleotide sequence selected from the group consisting of SEQ ID NOS: 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71 and 73.
The isolated polynucleotide of claim 23, in which the polynucleotide sequence that encodes the background partial or complete PIV genome comprises the complement of nucleotide sequences of SEQ ID NOS: 69, 71 and 73,
or in which the polynucleotide sequence that encodes the background PIV antigenome comprises nucleotide sequences of SEQ ID NOS: 69, 71 and 73.
The isolated polynucleotide of claim 24, in which the polynucleotide sequence that encodes the background partial or complete PIV genome comprises the complement of nucleotide sequences of SEQ ID NOS: 69, 71 and 73,
or in which the polynucleotide sequence that encodes the background PIV antigenome comprises nucleotide sequences of SEQ ID NOS: 69, 71 and 73.
The isolated polynucleotide of claim 23, in which the chimeric partial or complete PIV genome or antigenome comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein or of a F glycoprotein.
The isolated polynucleotide of claim 30, in which the heterologous PIV sequence is from HPIV1.
The isolated polynucleotide of claim 22, that comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein and a heterologous PIV sequence that encodes an open reading frame of a F glycoprotein.
The isolated polynucleotide of claim 32, in which both of the heterologous PIV sequences are from HPIV1.
The isolated polynucleotide of claim 22, in which the heterologous PIV sequence is a gene segment encoding a portion of an open reading frame of a HN or F glycoprotein comprising an antigenic domain or epitope or the cytoplasmic tail portion, of said HN or F glycoprotein and replaces the counterpart gene segment of said background PIV sequence to form an open reading frame encoding a chimeric glycoprotein.
An infectious parainfluenza virus (PIV) comprising a major nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), a large polymerase protein (L), and a partial or complete human PIV genome comprising at least one sequence selected from the group consisting of the complement of nucleotide sequences of SEQ ID NOS: 61, 63, 65, 67, 69, 71 and 73,
or a partial or complete human PIV antigenome comprising at least one nucleotide sequence selected from the group consisting of SEQ ID NOS: 61, 63, 65, 67, 69, 71 and 73.
The infectious PIV of claim 35, in which the human partial or complete PIV genome or antigenome is a human PIV3 genome or antigenome.
An infectious parainfluenza virus (PIV) comprising a major nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), a large polymerase protein (L), and a human partial or complete PIV genome comprising the complement of nucleotide sequences of SEQ ID NOS: 69, 71, and 73,
or a partial or complete human PIV antigenome comprising the nucleotide sequences of SEQ ID NOS: 69, 71, and 73.
The infectious PIV of claim 37, in which the human partial or complete PIV genome or antigenome is a human PIV3 genome comprising the complement of nucleotide sequences of SEQ ID NOS: 69, 71 and 73, or a partial or complete human PIV3 antigenome comprising the nucleotide sequences of SEQ ID NOS: 69, 71 and 73.
An infectious chimeric parainfluenza virus (PIV) comprising a major nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), a large polymerase protein (L), and a chimeric partial or complete PIV genome or antigenome comprising a a background partial or complete PIV genome or antigenome and at least one heterologous PIV sequence selected from a HPIV 1 sequence, a HPIV 2 sequence, a HPIV 3 sequence a BPIV sequence or a MPIV sequence,
wherein said chimeric partial or complete PIV genome or antigenome comprises a polynucleotide encoding the L protein of the wild-type of said background PIV or of said heterologous PIV.
The infectious chimeric PIV of claim 39, in which the background partial or complete PIV genome or antigenome further includes at least one mutation at a position corresponding to a position in the genome of HPIV3 selected from the group consisting of Val96 of the N protein, Ser389 of the N protein, Pro199 of the M protein, Ile96 of the C protein, Ile420 of the F protein, Ala450 of the F protein, Val384 of the HN protein, nucleotide 23 of the 3′ leader sequence, nucleotide 24 of the 3′ leader sequence, nucleotide 28 of the 3′ leader sequence, nucleotide 45 of the 3′ leader sequence and nucleotide 62 in the N gene start sequence.
The infectious chimeric PIV of claim 39, in which the chimeric partial or complete PIV genome or antigenome comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein or of a F glycoprotein.
The infectious chimeric PIV of claim 40, in which the chimeric partial or complete PIV genome or antigenome comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein or of a F glycoprotein.
The infectious chimeric PIV of claim 40, in which the heterologous PIV sequence is from HPIV1.
The infectious chimeric PIV of claim 41, in which the heterologous PIV sequence is from HPIV1.
The infectious chimeric PIV of claim 39, in which the chimeric partial or complete PIV genome or antigenome comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein and a heterologous PIV sequence that encodes an open reading frame of a F glycoprotein.
The infectious chimeric PIV of claim 40, in which the chimeric partial or complete PIV genome or antigenome comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein and a heterologous PIV sequence that encodes an open reading frame of a F glycoprotein.
The infectious chimeric PIV of claim 45, in which both of the heterologous PIV sequences are from HPIV1.
The infectious chimeric PIV of claim 46, in which both of the heterologous PIV sequences are from HPIV1.
The infectious chimeric PIV of claim 45, in which the heterologous PIV sequence is a gene segment encoding a portion of an open reading frame of a HN or F glycoprotein comprising an antigenic domain or epitope or the cytoplasmic tail portion of said HN or F glycoprotein and replaces the counterpart gene segment of said background PIV sequence to form an open reading frame encoding a chimeric glycoprotein.
An infectious chimeric PIV virus comprising a chimeric partial or complete PIV genome or antigenome that includes at least one point mutation comprising said chimeric partial or complete PIV genome or antigenome,
wherein said chimieric partial or complete PIV genome or antigenome comprises a polynucleotide sequence of a background partial or complete PIV genome or antigenome and at least one heterologous PIV sequence selected from a HPIV 1 sequence, a HPIV 2 sequence, a HPIV 3 sequence a BPIV sequence or a MPIV sequence,

and wherein said polynucleotide sequence encoding said partial or complete PIV genome or antigenome comprises a polynucleotide encoding the L protein of the wild-type of said background PIV or of said heterologous PIV.
The infectious chimeric PIV of claim 50, in which the chimeric partial or complete PIV genome or antigenome comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein or of a F glycoprotein.
The infectious chimeric PIV of claim 50, in which the heterologous PIV sequence is from HPIV1.
The infectious chimeric PIV of claim 51, in which the heterologous PIV sequence is from HPIV1.
The infectious chimeric PIV of claim 50, in which the chimeric partial or complete PIV genome or antigenome comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein and a heterologous PIV sequence that encodes a F glycoprotein.
The infectious chimeric PIV of claim 54, in which both of the heterologous PIV sequences are from HPIV1.
An infectious chimeric PIV comprising a chimeric partial or complete PIV genome or antigenome,
wherein said chimeric partial or complete PIV genome or antigenome comprises a background partial or complete PIV genome or antigenome and at least one heterologous PIV polynucleotide sequence selected from a HPIV 1 sequence, a HPIV 2 sequence, a HPIV 3 sequence a BPIV sequence or a MPIV sequence,

wherein said heterologous PIV polynucleotide sequence comprises a transcription unit comprising a polynucleotide sequence encoding an open reading frame of a protein of said heterologous PIV or portion thereof providing an antigenic determinant that is inserted between a gene start sequence and a gene end sequence of the PIV of the background.
The infectious chimeric PIV of claim 56, in which the heterologous PIV polynucleotide sequence replaces an open reading frame of a gene of the background PIV.
The infectious chimeric PIV of claim 56, in which the heterologous PIV nucleotide sequence is added to the genome or antigenome of the background PIV.
The infectious chimeric PIV of claim 56, in which the background partial or complete PIV genome or antigenome further includes at least one mutation at a position corresponding to a position in the genome of HPIV3 selected from the group consisting of Val96 of the N protein, Ser389 of the N protein, Ile96 of the C protein, Pro199 of the M protein, Ile420 of the F protein, Ala450 of the F protein, Val384 of the HN protein, Tyr942 of the L protein, Leu992 of the L protein, Thr1558 of the L protein, nucleotide 23 of the 3′ leader sequence, nucleotide 24 of the 3′ leader sequence, nucleotide 28 of the 3′ leader sequence, nucleotide 45 of the 3′ leader sequence and nucleotide 62 in the N gene start sequence.
The infectious chimeric PIV of claim 56, in which the background partial or complete PIV genome or antigenome further includes mutations at positions corresponding to a position in the genome of HPIV3 of Tyr942 of the L protein, Leu992 of the L protein and Thr1558 of the L protein.
The infectious chimeric PIV of claim 56, in which the background partial or complete PIV genome comprises at least one nucleotide sequence that is the complement of a sequence selected from the group consisting of SEQ ID NOS: 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71 and 73
or in which the background PIV antigenome comprises at least one nucleotide sequence selected from the group consisting of SEQ ID NOS: 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71 and 73.
The infectious chimeric PIV of claim 57, in which background partial or complete PIV genome comprises the complement of nucleotide sequences of SEQ ID NOS: 69, 71 and 73,
or in which the background PIV antigenome comprises nucleotide sequences of SEQ ID NOS: 69, 71 and 73.
The infectious chimeric PIV of claim 58, in which the background partial or complete PIV genome comprises the complement of nucleotide sequences of SEQ ID NOS: 69, 71 and 73,
or in which the background PIV antigenome comprises nucleotide sequences of SEQ ID NOS: 69, 71 and 73.
The infectious chimeric PIV of claim 57, in which the chimeric partial or complete PIV genome or antigenome comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein or of a F glycoprotein.
The infectious chimeric PIV of claim 64, in which the heterologous PIV sequence is from HPIV1.
The infectious chimeric PIV of claim 56, in which the chimeric partial or complete PIV genome or antigenome comprises a heterologous PIV sequence that encodes an open reading frame of a HN glycoprotein and a heterologous PIV sequence that encodes an open reading frame of a F glycoprotein.
The infectious chimeric PIV of claim 66, in which both of the heterologous PIV sequences are from HPIV1.
The infectious chimeric PIV of claim 56, in which the heterologous PIV sequence is a gene segment encoding a portion of an open reading frame of a HN or F glycoprotein comprising an antigenic domain or epitope or the cytoplasmic tail portion of said HN or F glycoprotein and replaces the counterpart gene segment of said background PIV sequence to form an open reading frame encoding a chimeric glycoprotein.
An immunogenic composition comprising the infectious PIV of any one of claims 65–46 and 47–68.
A method for making a PIV, comprising expressing the isolated polynucleotide of any one of claims 1–12 and 13–34 in a cell or in a cell-free lysate, said cell or cell-free lysate comprising a major nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P) and a large polymerase protein (L) of a human or bovine PIV.

Owners (US)

Health And Human Services Government Of The United States Of America The As Represented By The Department Of (Jul 01 1998)
Explore more patents:
- View all patents where Owners (US) HEALTH AND HUMAN SERVICES GOVERNMENT OF THE UNITED STATES OF AMERICA THE AS REPRESENTED BY THE DEPARTMENT OF

Applicants

Us Health
Explore more patents:
- View all patents where Applicants US HEALTH

Inventors

Murphy Brian R
Explore more patents:
- View all patents where Inventors MURPHY BRIAN R
Collins Peter L
Explore more patents:
- View all patents where Inventors COLLINS PETER L
Durbin Anna P
Explore more patents:
- View all patents where Inventors DURBIN ANNA P
Skiadopoulos Mario H
Explore more patents:
- View all patents where Inventors SKIADOPOULOS MARIO H
Tao Tao
Explore more patents:
- View all patents where Inventors TAO TAO

CPC Classifications

C07K16/1027
Explore more patents:
- View all patents where CPC Classifications C07K16/1027
- View in Classification Explorer
A61K39/00
Explore more patents:
- View all patents where CPC Classifications A61K39/00
- View in Classification Explorer
A61K2039/5254
Explore more patents:
- View all patents where CPC Classifications A61K2039/5254
- View in Classification Explorer
C07K14/005
Explore more patents:
- View all patents where CPC Classifications C07K14/005
- View in Classification Explorer
C07K2319/00
Explore more patents:
- View all patents where CPC Classifications C07K2319/00
- View in Classification Explorer
C12N7/00
Explore more patents:
- View all patents where CPC Classifications C12N7/00
- View in Classification Explorer
C12N2760/18622
Explore more patents:
- View all patents where CPC Classifications C12N2760/18622
- View in Classification Explorer
C12N2760/18643
Explore more patents:
- View all patents where CPC Classifications C12N2760/18643
- View in Classification Explorer
C12N2760/18661
Explore more patents:
- View all patents where CPC Classifications C12N2760/18661
- View in Classification Explorer

IPC Classifications

A61K39/155
Explore more patents:
- View all patents where IPC Classifications A61K39/155
- View in Classification Explorer
A61K39/00
Explore more patents:
- View all patents where IPC Classifications A61K39/00
- View in Classification Explorer
C07K14/115
Explore more patents:
- View all patents where IPC Classifications C07K14/115
- View in Classification Explorer
C12N7/00
Explore more patents:
- View all patents where IPC Classifications C12N7/00
- View in Classification Explorer

US Classifications

424/211.1
Explore more patents:
- View all patents where US Classifications 424/211.1
- View in Classification Explorer
424/199.1
Explore more patents:
- View all patents where US Classifications 424/199.1
- View in Classification Explorer
435/235.1
Explore more patents:
- View all patents where US Classifications 435/235.1
- View in Classification Explorer
435/325
Explore more patents:
- View all patents where US Classifications 435/325
- View in Classification Explorer
435/320.1
Explore more patents:
- View all patents where US Classifications 435/320.1
- View in Classification Explorer
536/23.72
Explore more patents:
- View all patents where US Classifications 536/23.72
- View in Classification Explorer

Download PDF

Document Preview

Document History

Publication: Apr 24, 2007
US 7208161 B1
Application: May 22, 1998
US 8379398 A
Priority: May 22, 1998
US 8379398 A
Priority: Sep 19, 1997
US 5938597 P
Priority: May 23, 1997
US 4757597 P

Download Citation